SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001171000-15-000002
Filing Date
2015-02-04
Accepted
2015-02-04 19:44:14
Documents
2
Period of Report
2015-02-04

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 3  
1 PRIMARY DOCUMENT primary_doc.xml 3 12081
2 LIMITED POWER OF ATTORNEY farrelllpoa.txt EX-24 4093
  Complete submission text file 0001171000-15-000002.txt   17784
Mailing Address NATL INST FOR BIOPROCESSING RESEARCH FOSTERS AVENUE, MOUNT MERRION BLACKROCK CO. DUBLIN L2 00000
Business Address NATL INST FOR BIOPROCESSING RESEARCH FOSTERS AVENUE, MOUNT MERRION BLACKROCK CO. DUBLIN L2 00000 353 1 215 8100
Nexvet Biopharma plc (Issuer) CIK: 0001618561 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NEXVET BIOPHARMA PLC NATL INST, FOSTERS AVENUE, MOUNT MERRION BLACKROCK L2 00000
Business Address
Farrell Geraldine T (Reporting) CIK: 0001632385 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36828 | Film No.: 15577113